Ask a Question
    • NUBEQA®
    • Efficacy
    • Safety
    • Dosing
    • Reimbursement
    • Resources

    NUBEQA® Tools and Resources

    NUBEQA Dosing Card

    NUBEQA® Dosing Guide

    Download
    mCSPC Brochure

    NUBEQA® mCSPC Brochure

    Download
    nmCRPC Brochure

    NUBEQA® nmCRPC Brochure

    Donwload
    Patient Support Porgram

    PSP Enrolment Form for mCSPC

    Download
    Estimator

    Androgen Receptor Inhibitor Incremental Adverse Event Estimator

    Access
    NUBEQA® Homepage
    arrow_forward

    Click

    here
    for additional safety information and for a link to the product monograph

     

    NUBEQA (darolutamide) is indicated for the treatment of:
    •    patients with non-metastatic castration resistant prostate cancer (nmCRPC). NUBEQA has not been studied in patients with nmCRPC at low risk of developing metastases. The benefit and risk profile in these patients is unknown.
    •    patients with metastatic castration-sensitive prostate cancer (mCSPC).
    •    patients with metastatic castration-sensitive prostate cancer (mCSPC) in combination with docetaxel.
     

    See the Product Monograph

    here
    for important information about:
    •    Relevant warnings and precautions regarding monitoring for signs and symptoms of ischemic heart disease, drug-induced liver injury with increases in ALT and AST, risk of seizure, harm to developing fetus or loss of pregnancy, use of effective contraception, impaired fertility, monitoring for disease progression and PSA.
    •    Conditions of clinical use, adverse reactions, drug interactions and dosing instructions.

     

    The Product Monograph is also available by calling Bayer Medical Information at 1-800-265-7382.

    PP-NUB-CA-0686-2